Cyxone's development substance T20K's capacity to prevent and inhibit multiple sclerosis in animal models now verified by independent studyMarch 10, 2017 13:00 (CET)Regulatory
- December 21, 2016 14:00 (CET)Regulatory
Today, Cyxone announce that they will acquire the entire family of patents protecting the Company's main candidate T20K, from the Medical University of Vienna. The cost of € 100,930 includes VAT and corresponds to the costs of the patenting process.
- December 19, 2016 09:35 (CET)Regulatory
Cyxone announce that T20K demonstrates no measurable toxic effect in mice after oral administration of up to 100 mg/kg in a single dose. Even at an oral dose of 250 mg/kg, half of the animals recovered well after treatment. Low toxicity of injected T20K has previously been reported by Cyxone.
- November 21, 2016 09:02 (CET)Regulatory
- September 19, 2016 14:45 (CEST)Regulatory
- August 31, 2016 16:43 (CEST)Regulatory
Cyxone has completed its first toxicity study of drug candidate T20K for the treatment of Multiple Sclerosis (MS) through the LPT Laboratory of Pharmacology and Toxicology GmbH in Germany.